IDH2 and astrocytoma (excluding glioblastoma): A recent Cancer Genome Atlas Research showed IDH mutations had significant survival prediction in lower grade gliomas (WHO II and III), including oligodendroglioma, oligoastrocytoma and astrocytoma.